Celltrion CEO Cites Pfizer, J&J and Sanofi As Potential Buyers For Biosimilars Business
This article was originally published in PharmAsia News
Executive Summary
Although Korea’s Celltrion is not in takeover talks yet, CEO Seo Jung-jin named potential buyers after announcing he would sell his stake in the company he founded. Celltrion is expecting approval shortly in Europe for a biosimilar of J&J’s Remicade.